C4 Therapeutics, Inc. - Common Stock (NQ:CCCC)

2.880 -0.110 (-3.68%)

Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about C4 Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 17, 2023

From C4 Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

July 06, 2023

Via Benzinga

Nasdaq Edges Lower Following Fed Minutes; C4 Therapeutics Shares Jump ↗

July 05, 2023

U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones dropping around 100 points on Wednesday. The Dow traded down 0.30% to 34,316.70 while the NASDAQ fell 0.04% to 13,811.43....

Via Benzinga

Crude Oil Rises Sharply; Impel Pharmaceuticals Shares Spike Higher ↗

July 05, 2023

U.S. stocks traded lower midway through trading, with the Dow Jones dropping over 50 points on Wednesday. The Dow traded down 0.17% to 34,361.31 while the NASDAQ fell 0.14% to 13,797.72. The S&P 500,...

Via Benzinga

C4 Therapeutics Inc. (NASDAQ: CCCC) Highlighted for Surprising Price Action

May 30, 2023

Via Investor Brand Network

The Latest Analyst Ratings for C4 Therapeutics ↗

May 30, 2023

Via Benzinga

Looking Into C4 Therapeutics's Return On Capital Employed ↗

May 18, 2023

Via Benzinga

Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

July 05, 2023

Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares surged 87% to $11.78 after the company said the initial data from Phase 2 trial of Ixempra shows potential for improved clinical benefit in...

Via Benzinga

C4 Therapeutics Inc. (NASDAQ: CCCC) is One of Wednesday Morning’s Most Active Stocks

July 05, 2023

Via Investor Brand Network

Dow Drops 150 Points; US Factory Orders Increase 0.3% In May ↗

July 05, 2023

U.S. stocks traded lower this morning, with the Dow Jones dropping over 150 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.46% to 34,259.45 while the NASDAQ fell...

Via Benzinga

Expert Ratings for C4 Therapeutics ↗

May 08, 2023

Via Benzinga

Recap: C4 Therapeutics Q1 Earnings ↗

May 04, 2023

Via Benzinga

Where C4 Therapeutics Stands With Analysts ↗

March 28, 2023

Via Benzinga

Looking Into C4 Therapeutics's Return On Capital Employed ↗

February 28, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

July 05, 2023

Via Benzinga

C4 Therapeutics Stock Is Surging: What's Going On? ↗

July 05, 2023

C4 Therapeutics Inc (NASDAQ: CCCC) shares are rising Wednesday after the clinical-stage biopharmaceutical company announced the FDA cleared its investigational new drug (IND)

Via Benzinga

C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer

July 05, 2023

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer

June 20, 2023

From C4 Therapeutics, Inc.

Via GlobeNewswire

Week In Review: Betta Pharma Enters $392 Million Deal For C4 Therapeutics’ NSCLC Drug ↗

June 03, 2023

Hangzhou Betta Pharma acquired greater China rights for a novel non-small cell lung cancer drug from Boston’s C4 Therapeutics in a deal worth up to $392 million. Additionally, Lynk Pharma of Hangzhou...

Via Talk Markets

The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗

June 02, 2023

Big Pharma is facing a patent cliff that could siphon off billions in revenue.

Via Investor's Business Daily

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC

May 30, 2023

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 04, 2023

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

April 19, 2023

From C4 Therapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2023 ↗

February 24, 2023

Via Benzinga

Why Fulcrum Therapeutics Shares Are Trading Lower By Over 55%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

February 24, 2023

Gainers Bridger Aerospace Group Holdings, Inc. (NASDAQ: BAER) shares jumped 129.6% to $10.15. Jeffrey E. Kelter reported a 22.4% stake in a 13D filing on Thursday.

Via Benzinga

C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

February 23, 2023

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics to Present at Two Virtual February 2023 Conferences

February 08, 2023

From C4 Therapeutics, Inc.

Via GlobeNewswire

Ford, Atlassian, Amazon And Other Big Stocks Moving Lower On Friday ↗

February 03, 2023

U.S. stocks traded lower, with the Dow Jones dropping over 100 points on Friday. Here are some big stocks recording losses in today’s session.

Via Benzinga

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors

January 30, 2023

From C4 Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

January 25, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.